Immunoexpression of HBME-1, high molecular weight cytokeratin, cytokeratin 19, thyroid transcription factor-1, and E-cadherin in thyroid carcinomas

被引:39
作者
Choi, YL
Kim, MK
Suh, JW
Han, J
Kim, JH
Yang, JH
Nam, SJ
机构
[1] Sungkyunkwan Univ, Sch Med, Dept Pathol, Seoul, South Korea
[2] Sungkyunkwan Univ, Sch Med, Div Brest Endocrine Surg, Seoul, South Korea
[3] Sungkyunkwan Univ, Sch Med, Dept Surg, Samsung Med Ctr, Seoul, South Korea
关键词
HBME-1; antiger; keratin; thyroid nuclear factor 1; cadherins; thyroid neoplasms;
D O I
10.3346/jkms.2005.20.5.853
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To examine the immunohistochemical alterations associated with the histological dedifferentiation of thyroid carcinomas, we performed staining for HBME-1, high molecular weight cytokeratin (HCK), CK 19, thyroid transcription factor-1 (TTF-1) and E-cadherin (E-CD) on 125 various types of thyroid carcinomas. The HBME-1 staining was strong and diffuse in follicular carcinoma (FC), papillary carcinoma (PC), and poorly differentiated carcinoma (PDC), while it was rare in undifferentiated carcinoma (UC) as well as in benign lesions. Strong, diffuse staining for CK19 and HCK was predominantly found in PC, and these markers were not much found in other carcinomas. TTF-1 uniformly stained the tumor cells of all cases of PC, FC and Hurthle cell carcinome. (HC) and 42% of the PDC, while there was only focal staining in one case of the UC. Compared to the strong, diffuse reactivity in the benign lesions, E-CD staining was noted in 67% of PC, 80% of FC, 83% of HC, 58% of PDC and none of the UC. These results suggest that HBME-1 may be a marker for well-differentiated carcinomas while CK19 and HCK are phenotypic markers for papillary carcinoma. The loss or reduced expression of TTF-1 and E-CD may be markers for dedifferentiation.
引用
收藏
页码:853 / 859
页数:7
相关论文
共 24 条
[1]  
[Anonymous], 1990, Surgical pathology of the thyroid
[2]   Differential expression of cytokeratins in follicular variant of papillary carcinoma: An immunohistochemical study and its diagnostic utility [J].
Baloch, ZW ;
Abraham, S ;
Roberts, S ;
LiVolsi, VA .
HUMAN PATHOLOGY, 1999, 30 (10) :1166-1171
[3]  
BRABANT G, 1993, CANCER RES, V53, P4987
[4]   REGULATION OF THE CELL-CELL ADHESION PROTEIN, E-CADHERIN, IN DOG AND HUMAN THYROCYTES IN-VITRO [J].
BRABANT, G ;
HOANGVU, C ;
BEHRENDS, J ;
CETIN, Y ;
POTTER, E ;
DUMONT, JE ;
MAENHAUT, C .
ENDOCRINOLOGY, 1995, 136 (07) :3113-3119
[5]   Cytokeratin subtypes in thyroid tumours: Immunohistochemical study with emphasis on the follicular variant of papillary carcinoma [J].
Cameron, BR ;
Berean, KW .
JOURNAL OF OTOLARYNGOLOGY, 2003, 32 (05) :319-322
[6]   Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3, and HBME-1 [J].
Casey, MB ;
Lohse, CM ;
Lloyd, RV .
ENDOCRINE PATHOLOGY, 2003, 14 (01) :55-60
[7]  
Cerrato A, 1998, J PATHOL, V185, P267
[8]  
Garcia-Rostan G, 1999, CANCER RES, V59, P1811
[9]  
Graff JR, 1998, CANCER RES, V58, P2063
[10]   Thyroid transcription factor-1 in normal, hyperplastic, and neoplastic follicular thyroid cells examined by immunohistochemistry and nonradioactive in situ hybridization [J].
Katoh, R ;
Kawaoi, A ;
Miyagi, E ;
Suzuki, K ;
Nakamura, Y ;
Kakudo, K .
MODERN PATHOLOGY, 2000, 13 (05) :570-576